Nilmat (Nilotinib)

Nilotinib selectively binds to the ATP‑binding pocket of the BCR‑ABL fusion protein, blocking its kinase activity. This interruption stops downstream signaling pathways that promote cell proliferation and survival, leading to reduced growth of malignant cells and increased apoptosis in CML.

The dosing regimen for Nilmat is determined by the prescribing physician based on the patient’s clinical condition, disease phase, and tolerance. Healthcare providers follow approved guidelines and adjust the dose as needed; patients should follow the prescriber’s instructions exactly.

Safety data for nilotinib during pregnancy and lactation are limited. It is generally advised to avoid use unless the potential benefit outweighs the risk. Women of childbearing potential should use effective contraception, and breastfeeding is not recommended while receiving treatment.

To request Nilmat, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative to nilotinib is imatinib, another BCR‑ABL inhibitor. Nilotinib is more potent and can be effective in patients who are resistant or intolerant to imatinib, but it may have a higher risk of QT prolongation and requires careful cardiac monitoring.

Nilmat should be stored at ambient temperature, below 25 °C, in its original packaging to protect from moisture and light. Keep the product out of reach of children and do not store in humid or excessively hot environments.

Nilmat is taken orally, usually with a low‑fat meal to improve absorption. The tablets should be swallowed whole with water and not crushed or chewed. Patients should follow the dosing schedule prescribed by their healthcare provider.

The most serious adverse events include QT interval prolongation, which can lead to serious cardiac arrhythmias, severe pancreatitis, and hepatic failure. Patients should report symptoms such as palpitations, abdominal pain, jaundice, or unexplained fatigue to their physician promptly.

Nilmat is contraindicated in patients with a known history of prolonged QT interval, uncontrolled cardiac disease, severe hepatic impairment, or active pancreatitis. It should also be avoided in individuals taking strong CYP3A4 inhibitors or other QT‑prolonging medications without close medical supervision.